Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

Journal of International Medical Research

Volumn 25, Issue 1, 1997, Pages 24-32

  Syvalahti E K G ^a   Taiminen, T ^a   Saarijarvi S ^a   Lehto, H ^b   Niemi, H ^b   Ahola, V ^a   Dahl, M L ^c   Salokangas, R K R ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b H LUNDBECK A S   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Citalopram; Drug interactions; Neuroleptics; Oxidative drug metabolism; Pharmacokinetics; Schizophrenic patients; Selective serotonin re uptake inhibitors

Indexed keywords

CHLORPROMAZINE; CITALOPRAM; DEBRISOQUINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OXYGENASE; PERPHENAZINE; SEROTONIN UPTAKE INHIBITOR; SPARTEINE HYDROXYLASE; THIORIDAZINE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL;

ADULT; AEROBIC METABOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 1842403585     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500104     Document Type: Article

References (30)

1. Breirer A, Schreiber JL, Dyer J, et al: National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 48: 239-246.
2. Bartels SJ, Drake RE: Depressive symptoms in schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1988; 52: 467-483.
3. Taiminen TJ, Kujari H: Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. Acta Psychiatr Scand 1994; 90: 247 -251.
4. Boyer WF, Feighner JP: Other potential indications for selective serotonin re-uptake inhibitors. In: Selective serotonin re-uptake inhibitors (Feighner JP and Boyer WF, eds.) J Wiley & Sons Ltd, Chichester 1991; pp. 119-132.
5. Michels R, Marzuk PM: Progress in psychiatry. N Engl J Med 1993; 329:628-638.
6. Saxena S, Wnag D, Bystritsky A, et al: Risperidone augmentation of SSRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57: 303-306.
7. Brøsen K, Gram LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537-547.
8. Bertilsson L, Dahl M-L: Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-223.
9. Hyttel J, Larsen J-J: Serotonin selective antidepressants. Acta Pharmacol Toxicol 1985; 56: 146-153.
10. 2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology 1996; 126: 277-280.
11. Kallioniemi H, Syvälahti E: Citalopram, a specific inhibitor of serotonin reuptake in treatment of psychotic and borderline patients. Nord J Psychiatry 1992; 46: 181-187.
12. Syvälahti EKG, Kallioniemi H, Lehto H: Citalopram in patients with unsatisfactory response to neuroleptics: an open follow-up study. Meth Find Exp Clin Pharmacol 1994; 16: 49-55.
13. Øyehaug E, Østensen ET, Salvesen B: HPLC determination of citalopram and its four metabolites in plasma and urine samples for psychiatric patients. J Chromatogr B Biomed Appl 1994; 308: 199-208.
14. Crewe HK, Lennard MS, Tucker GT, et al: The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-265.
15. Skjelbo E, Brøsen K: Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256-261.
16. Heim M, Meyer VA: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplication. Lancet 1990; 336: 529-532.
17. Salokangas RKR, Saarijärvi S, Taiminen T, et al: Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175-180.
18. Gram LF: Fluoxetine. N Engl J Med 1994; 331: 1354-1361.
19. Coulter DM, Pillans PI: Fluoxetine and extrapyramidal side-effects. Am J Psychiatry 1995; 152: 122-125.
20. Sindrup SH, Brøsen K, Hansen MGJ, et al: Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11-17.
21. Vaughan DA: Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988; 145: 1478.
22. von Bahr C, Movin G, Nordin C, et al: Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234-240.
23. Syvälahti EKG, Lindberg R, Kallio J, et al: Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986; 21: 89-92.
24. Goff DC, Brotman AW, Waites M, et al: Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492-494.
25. Ames D, Wirshing WC, Marder SR, et al: Fluoxetine in haloperidol-stabilized schizophrenics. The 146th Annual Meeting of the APA, 22-27 May 1993. Program and Abstracts on New Research: 76.
26. Linnet K: Comparison of the kinetic interactions of the neuroleptics per-phenazine and zuclopenthixol with tricyclic antidepressives. Ther Drug Monit 1995; 17: 308-311.
27. Gram LF, Hansen MGJ, Sindrup SH, et al: Citalopram: Interaction studies with levomepromazine, imipramine and lithium. Ther Drug Monit 1993; 15: 18-24.
28. Linnet K, Wiborg D: Steady-state serum concentrations of the neuroleptic per-phenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996; 60: 41-47.
29. Leinonen E, Lepola U, Koponen H, et al: The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996; 18: 111-117.
30. Baumann P, Larsen F: The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995; 6: 287-295.